124 related articles for article (PubMed ID: 38171144)
1. Impact of Hyperglycemia on Complication and Mortality after Transarterial Chemoembolization for Hepatocellular Carcinoma.
Moon SJ; Ahn CH; Lee YB; Cho YM
Diabetes Metab J; 2024 Mar; 48(2):302-311. PubMed ID: 38171144
[TBL] [Abstract][Full Text] [Related]
2. Incidence, risk factors, and prognosis of acute kidney injury following transarterial chemoembolization in patients with hepatocellular carcinoma: a prospective cohort study.
Hao JF; Zhang LW; Bai JX; Li YJ; Liu JN; Zhang XL; Han JM; Li X; Jiang H; Cao N
Indian J Cancer; 2015 Feb; 51 Suppl 2():e3-8. PubMed ID: 25712839
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors for acute kidney injury following transarterial chemoembolization in patients with hepatocellular carcinoma.
Zhou C; Wang R; Ding Y; Du L; Hou C; Lu D; Hao L; Lv W
Int J Clin Exp Pathol; 2014; 7(5):2579-86. PubMed ID: 24966972
[TBL] [Abstract][Full Text] [Related]
4. Acute Kidney Injury in Adult Patients With Hepatocellular Carcinoma After TACE or Hepatectomy Treatment.
Mou Z; Guan T; Chen L
Front Oncol; 2022; 12():627895. PubMed ID: 35686095
[TBL] [Abstract][Full Text] [Related]
5. Effect of acute kidney injury on the patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
Sohn W; Ham CB; Kim NH; Kim HJ; Cho YK; Jeon WK; Kim BI
PLoS One; 2020; 15(12):e0243780. PubMed ID: 33315944
[TBL] [Abstract][Full Text] [Related]
6. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
[TBL] [Abstract][Full Text] [Related]
7. Tumor Size Affects Efficacy of Adjuvant Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma and Microvascular Invasion.
Liu S; Li H; Guo L; Zhang B; Zhou B; Zhang W; Zhou J; Fan J; Ye Q
Oncologist; 2019 Apr; 24(4):513-520. PubMed ID: 30552155
[TBL] [Abstract][Full Text] [Related]
8. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
[No Abstract] [Full Text] [Related]
9. Balloon-occluded transarterial chemoembolization versus conventional transarterial chemoembolization for the treatment of single hepatocellular carcinoma: a propensity score matching analysis.
Chu HH; Gwon DI; Kim GH; Kim JH; Ko GY; Shin JH; Ko HK; Yoon HK
Eur Radiol; 2023 Apr; 33(4):2655-2664. PubMed ID: 36472699
[TBL] [Abstract][Full Text] [Related]
10. Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis.
Bargellini I; Lorenzoni V; Lorenzoni G; Scalise P; Andreozzi G; Bozzi E; Giorgi L; Cervelli R; Scandiffio R; Perrone O; Meccia DV; Boccuzzi A; Daviddi F; Cicorelli A; Lunardi A; Crocetti L; Turchetti G; Cioni R
Eur Radiol; 2021 Oct; 31(10):7512-7522. PubMed ID: 33871708
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis.
Zhao S; Zhou M; Wang P; Yang J; Zhang D; Yin F; Song P
Technol Cancer Res Treat; 2022; 21():15330338221133640. PubMed ID: 36259214
[No Abstract] [Full Text] [Related]
12. The impact of transarterial chemoembolization induced complications on outcomes after liver transplantation: A propensity-matched study.
Boteon APCDS; Boteon YL; Vinuela EF; Derosas C; Mergental H; Isaac JR; Muiesan P; Mehzard H; Ma YT; Shah T; Mirza DF; Perera MTPR
Clin Transplant; 2018 May; 32(5):e13255. PubMed ID: 29637619
[TBL] [Abstract][Full Text] [Related]
13. Acute kidney injury after transarterial chemoembolization for hepatocellular carcinoma: a retrospective analysis.
Park J; Chung HC; Lee JS; Lee BM; Kim DM; Hwang JC; Jo MW; Noh M; Shin JW
Blood Purif; 2008; 26(5):454-9. PubMed ID: 18810227
[TBL] [Abstract][Full Text] [Related]
14. Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib.
Wang J; Zhao M; Han G; Han X; Shi J; Mi L; Li N; Yin X; Duan X; Hou J; Yin F
Technol Cancer Res Treat; 2023; 22():15330338231166765. PubMed ID: 37161343
[No Abstract] [Full Text] [Related]
15. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Apatinib Compared with Conventional Transarterial Chemoembolization Plus Apatinib in the Treatment of Unresectable Hepatocellular Carcinoma.
Zhang W; Chen L; Cao Y; Sun B; Ren Y; Sun T; Zheng C
Cancer Manag Res; 2021; 13():5391-5402. PubMed ID: 34262347
[TBL] [Abstract][Full Text] [Related]
16. Transarterial chemoembolization combined with apatinib versus transarterial chemoembolization alone for hepatocellular carcinoma with macroscopic vascular invasion: A propensity score matching analysis.
Shen L; Chen S; Qiu Z; Qi H; Yuan H; Cao F; Xie L; Chen Q; Li W; Fan W
J Cancer Res Ther; 2020 Sep; 16(5):1063-1068. PubMed ID: 33004748
[TBL] [Abstract][Full Text] [Related]
17. Transarterial Chemoembolization Monotherapy Versus Combined Transarterial Chemoembolization-Microwave Ablation Therapy for Hepatocellular Carcinoma Tumors ≤5 cm: A Propensity Analysis at a Single Center.
Chen QF; Jia ZY; Yang ZQ; Fan WL; Shi HB
Cardiovasc Intervent Radiol; 2017 Nov; 40(11):1748-1755. PubMed ID: 28681222
[TBL] [Abstract][Full Text] [Related]
18. Delayed biopsy following completion of transarterial chemoembolization in patients with hepatocellular carcinoma: Effects on pathological outcomes and its advantages.
Zhi W; Hou J; Fan S; Han Y
J Cancer Res Ther; 2022 Sep; 18(5):1346-1351. PubMed ID: 36204882
[TBL] [Abstract][Full Text] [Related]
19. Transarterial Radioembolization versus Transarterial Chemoembolization Plus Percutaneous Ablation for Unresectable, Solitary Hepatocellular Carcinoma of ≥3 cm: A Propensity Score-Matched Study.
Yu Q; Thapa N; Karani K; Navuluri R; Ahmed O; Van Ha T
J Vasc Interv Radiol; 2022 Dec; 33(12):1570-1577.e1. PubMed ID: 36100064
[TBL] [Abstract][Full Text] [Related]
20. Risk of acute kidney injury after transarterial chemoembolisation in hepatocellular carcinoma patients: A nationwide population-based cohort study.
Lee BC; Liu KL; Lin CL; Kao CH
Eur Radiol; 2017 Nov; 27(11):4482-4489. PubMed ID: 28593432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
